Elubrixin free base

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 319713

CAS#: 688763-64-6 (free base)

Description: Elubrixin, also known as SB-656933 or SB-656933-AAF, is a interleukin 8 inhibitor and CXCR2 selective antagonist, which is potentially useful for Inflammatory bowel disease therapies. Elubrixin inhibits ex vivo neutrophil activation and ozone-induced airway inflammation in humans. demonstrates dose-dependent effects on neutrophil activation and recruitment within a well-tolerated dose range. SB-656933 may be an effective agent in neutrophil-predominant diseases.


Chemical Structure

img
Elubrixin free base
CAS# 688763-64-6 (free base)

Theoretical Analysis

MedKoo Cat#: 319713
Name: Elubrixin free base
CAS#: 688763-64-6 (free base)
Chemical Formula: C17H17Cl2FN4O4S
Exact Mass: 462.03
Molecular Weight: 463.305
Elemental Analysis: C, 44.07; H, 3.70; Cl, 15.30; F, 4.10; N, 12.09; O, 13.81; S, 6.92

Price and Availability

Size Price Availability Quantity
1g USD -1
2g USD -1
5g USD -1
Bulk inquiry

Related CAS #: 960495-43-6 (tosylate)   688763-64-6 (free base)   688763-65-7 (HCl)    

Synonym: SB-656933; SB 656933; SB656933; SB-656933-AAF; SB-656933 AAF; SB-656933AAF; Elubrixin

IUPAC/Chemical Name: 1-(4-chloro-2-hydroxy-3-(piperazin-1-ylsulfonyl)phenyl)-3-(2-chloro-3-fluorophenyl)urea

InChi Key: YQYFEGTYCUQBEI-UHFFFAOYSA-N

InChi Code: InChI=1S/C17H17Cl2FN4O4S/c18-10-4-5-13(23-17(26)22-12-3-1-2-11(20)14(12)19)15(25)16(10)29(27,28)24-8-6-21-7-9-24/h1-5,21,25H,6-9H2,(H2,22,23,26)

SMILES Code: FC1=C(Cl)C(NC(NC2=CC=C(Cl)C(S(=O)(N3CCNCC3)=O)=C2O)=O)=CC=C1

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 463.31 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Kaur M, Singh D. Neutrophil chemotaxis caused by chronic obstructive pulmonary
disease alveolar macrophages: the role of CXCL8 and the receptors CXCR1/CXCR2. J
Pharmacol Exp Ther. 2013 Oct;347(1):173-80. doi: 10.1124/jpet.112.201855. Epub
2013 Aug 2. PubMed PMID: 23912333.


2: Moss RB, Mistry SJ, Konstan MW, Pilewski JM, Kerem E, Tal-Singer R, Lazaar AL;
CF2110399 Investigators. Safety and early treatment effects of the CXCR2
antagonist SB-656933 in patients with cystic fibrosis. J Cyst Fibros. 2013
May;12(3):241-8. doi: 10.1016/j.jcf.2012.08.016. Epub 2012 Sep 17. PubMed PMID:
22995323.


3: Aul R, Patel S, Summerhill S, Kilty I, Plumb J, Singh D. LPS challenge in
healthy subjects: an investigation of neutrophil chemotaxis mechanisms involving
CXCR1 and CXCR2. Int Immunopharmacol. 2012 Jul;13(3):225-31. doi:
10.1016/j.intimp.2012.04.008. Epub 2012 May 2. PubMed PMID: 22561413.


4: Lazaar AL, Sweeney LE, MacDonald AJ, Alexis NE, Chen C, Tal-Singer R.
SB-656933, a novel CXCR2 selective antagonist, inhibits ex vivo neutrophil
activation and ozone-induced airway inflammation in humans. Br J Clin Pharmacol.
2011 Aug;72(2):282-93. doi: 10.1111/j.1365-2125.2011.03968.x. PubMed PMID:
21426372; PubMed Central PMCID: PMC3162658.


5: Nicholson GC, Tennant RC, Carpenter DC, Sarau HM, Kon OM, Barnes PJ, Salmon M,
Vessey RS, Tal-Singer R, Hansel TT. A novel flow cytometric assay of human whole
blood neutrophil and monocyte CD11b levels: upregulation by chemokines is related
to receptor expression, comparison with neutrophil shape change, and effects of a
chemokine receptor (CXCR2) antagonist. Pulm Pharmacol Ther. 2007;20(1):52-9. Epub
2006 Jan 6. PubMed PMID: 16406722.